Abstract
This study aimed to validate the value of tuberculostearic acid (TBSA) whether it could implicate the existence of M. tuberculosis and assist for clinical diagnosis of Tuberculous Meningitis (TBM). Gas Chromatography/mass spectrometry was used to detect TBSA in the chemically pretreated cerebrospinal fluid of suspected TBM patients. In total, 140 patients were admitted for our study included 27 confirm TBM patients and 50 TBSA positive patients. Sensitivity of 0.7407 (CI 95%: 0.5372-0.8889) and specificity of 0.7345 (CI 95%: 0.6432-0.8132) were calculated. The Lancet consensus scoring system was also applied to evaluate the possibility of TBM in suspected patients, finding that TBSA positive patients showed a similar distributive grouping as the definite TBM patients. Our study implicates that the prospective use of TBSA is worth combining into a scoring system for characterizing the features of Mtb, showing a great potential of TBM diagnosis by TBSA in the future.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR1900028161
Funding Statement
Our study was supported by funding from the Science and Technology Planning Project of Guangdong Province, China (Grant No. 2017B020247006) as well as the Natural Science Foundation of Guangdong Province, China (Grant No. 2016A030313579).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All patients were satisfied with the conditions of lumbar puncture and were informed consent for our research purpose and sample usage. The collected samples were kept in the CSF sample library of Department of Neurology in Nanfang Hospital. The study was approved by the Medical Ethics Committee of Nanfang Hospital (No. of approval letter: NFEC-2018-087)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail address of each author: Tsz Hei Fong (andrewfongth{at}163.com)
Wangpan Shi (subrosapan{at}gmail.com)
Siyi Li (siyisive{at}163.com)
Guanghui Liu (418861545{at}qq.com)
Chung Lam Ng (jessicangcl{at}outlook.com)
Haishan Jiang (jianghs{at}smu.edu.cn)
Data Availability
The data that support the findings of this study are available on request from the corresponding author, Haishan Jiang. The data are not publicly available due to the information could compromise the privacy of research participants.
